UPPALURI SUBBARAO V 4

4 · Winston Pharmaceuticals, Inc. · Filed Sep 28, 2009

Form 4

Period: 2009-09-24

Director

Transactions

Conversion
Warrants to purchase Common Stock
2009-09-24+89,589→ 89,589 total
Exercise: $0.39From: 2008-09-25Exp: 2012-11-13→ Common Stock (89,589 underlying)
Conversion
Series A Convertible Preferred Stock
2009-09-24−229→ 0 total
Exercise: $0.00→ Common Stock (229,000 underlying)
Conversion
Common Stock
2009-09-24+127,000→ 209,449 total
Conversion
Warrants to purchase Series A Convertible Preferred Stock
2009-09-24−89.589→ 0 total
Exercise: $392.72From: 2008-09-25Exp: 2012-11-13→ Series A Convertible Preferred Stock (89.589 underlying)

Footnotes (4)

[F1]Effective September 24, 2009, each outstanding share of Winston Pharmaceuticals, Inc. (the "Company") Series A Convertible Preferred Stock, par value $0.001 per share ("Series A Preferred Stock"), automatically converted into 1,000 shares of the Company's common stock, par value $0.001 per share ("Common Stock").
[F2]Reported amounts reflect share ownership subsequent to the effectuation by the Company on December 15, 2008 (the "Reverse Split Date") of a 1-for-8 reverse stock split whereby each eight shares of the Company's common stock and preferred stock either issued and outstanding or held as treasury shares immediately prior to the Reverse Split Date were automatically reduced and continued as one share of the Company's common stock or preferred stock, as applicable. All of the Company's outstanding securities were adjusted accordingly to reflect such reverse split.
[F3]Effective September 24, 2009, in connection with the automatic conversion of each outstanding share of Series A Preferred Stock into 1,000 shares of Common Stock, each outstanding warrant to purchase shares of Series A Preferred Stock, automatically converted into a warrant to purchase 1,000 shares of Common Stock at an exercise price of $0.39 per share.
[F4]Reported amounts exclude warrants reported elsewhere in this Form 4.

Documents

1 file